J. Scott Wolchko - 18 Nov 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
18 Nov 2021
Net transactions value
-$1,031,400
Form type
4
Filing time
22 Nov 2021, 16:45:38 UTC
Previous filing
25 Oct 2021
Next filing
12 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $54,000 +20,000 +5.1% $2.70 413,793 18 Nov 2021 Direct F1
transaction FATE Common Stock Sale $1,085,400 -20,000 -4.8% $54.27* 393,793 18 Nov 2021 Direct F1
transaction FATE Common Stock Award $0 +86,475 +22% $0.000000 480,268 19 Nov 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (right to buy) Options Exercise $0 -20,000 -20% $0.000000 79,446 18 Nov 2021 Common Stock 20,000 $2.70 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
F2 These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.
F3 This option is fully vested.